logo
Special care changes needed as costs push patients away

Special care changes needed as costs push patients away

Perth Now15-06-2025
High specialist medical costs cause almost two million Australians to delay or skip appointments, but a report suggests stripping public funding to doctors charging excessive fees could be part of the remedy.
About 1.9 million Australians are delaying or skipping critical medical care due to exorbitant fees for specialist doctors, a report by public policy think tank the Grattan Institute has found.
Some private specialist doctors charge patients two to three times more than the rate Medicare sets for those services, the report found.
It said patients of one specialist forked out an average of $300 per year in 2023 - up 73 per cent since 2010.
Average out-of-pocket costs for extreme-fee-charging specialists in 2023 reached $671 for psychiatry services and more than $350 for endocrinology, cardiology, paediatrics, immunology and neurology services.
The high costs leave critical health care out of reach for millions, causing patients in poorer pockets of Australia to wait months or years for urgent appointments, and leading to missed diagnoses, avoidable pain and added pressure on hospitals.
About four in 10 Australians visited a specialist in 2023/24.
About two-thirds across all specialties are private appointments, with patients receiving a Medicare rebate and paying a gap fee.
Grattan's Health Program director Peter Breadon said the system was broken from start to end.
"Everywhere, from how the system is planned and how training is funded through to how we target public investment and integrate the system between primary care and specialist care, it all really needs a lot of change," he told AAP.
Grattan's recommendations include scrapping Medicare subsidies to specialists who charge excessive fees and publicly naming them.
"Hopefully it would discourage those specialists who are charging really unreasonable fees, but this is a problem that needs many solutions," Mr Breadon said.
The report also recommends governments provide one million extra specialist appointment services every year in areas that receive the least care, a system in which GPs can get written advice from other specialists, modernise public specialist clinics, and allocate $160 million to expand specialist training for undersupplied specialties and rural training.
Australian Medical Association President Danielle McMullen said public hospital underinvestment and lagging Medicare rebates made it harder for patients.
"The risks of delaying medical care are that the health problem gets worse," she said, adding it also puts pressure on GPs and hospitals in public and private clinics.
The doctors' association supports most of Grattan's recommendations, but said removing Medicare funding from specialists who charged excessive fees was not practical.
As governments negotiate the National Health Reform agreement, Dr McMullen urged leaders to sort out longer-term funding for public hospitals and develop a health workforce data tracker to show where investment was needed.
Federal Health Minister Mark Butler said private health insurers and specialists needed to do more to protect patients from exorbitant bills.
He said the Albanese government would upgrade the Medical Costs Finder, which helps patients find the best value for specialist medical advice, and was committed to working with stakeholders to improve cost transparency.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Childcare boss accused of using bogus prescriptions to get opioids
Childcare boss accused of using bogus prescriptions to get opioids

Sydney Morning Herald

time8 hours ago

  • Sydney Morning Herald

Childcare boss accused of using bogus prescriptions to get opioids

A childcare director has been accused of fraudulently using staff Medicare numbers to get prescriptions for Panadeine Forte, a strong pain medication containing the opiate codeine, from different doctors in NSW's Hunter region. Hayley Challita was the director of Edukare Childcare and Preschool in Muswellbrook between April 2024 and March 2025. Four former staff members allege Challita used their Medicare numbers to obtain multiple prescriptions. EduKare has been contacted for comment, and the centre is not accused of wrongdoing. Challita did not respond to request for comment. The Herald has sighted eight prescriptions that four former colleagues say were obtained in their name but not at their request shortly after Challita asked for their Medicare details via text message which was also sighted by this masthead. Several colleagues, including a fifth staff member, also provided text messages from Challita purportedly asking them to give her Panadeine Forte from their own or their family's prescriptions. Paige Roy was employed as an educator at the centre and said that a few weeks into Challita starting as director, she asked her for her Medicare number to 'update employment records'. 'She said [the owner] was updating our portfolios on the company's childcare management system ... I just didn't think anything of it,' she said. Text messages between the pair allegedly show Challita asking for Roy's Medicare card on four separate occasions, with Challita using excuses including getting a new phone, updating Roy's emergency information and updating the staff management system.

Childcare boss accused of using bogus prescriptions to get opioids
Childcare boss accused of using bogus prescriptions to get opioids

The Age

time8 hours ago

  • The Age

Childcare boss accused of using bogus prescriptions to get opioids

A childcare director has been accused of fraudulently using staff Medicare numbers to get prescriptions for Panadeine Forte, a strong pain medication containing the opiate codeine, from different doctors in NSW's Hunter region. Hayley Challita was the director of Edukare Childcare and Preschool in Muswellbrook between April 2024 and March 2025. Four former staff members allege Challita used their Medicare numbers to obtain multiple prescriptions. EduKare has been contacted for comment, and the centre is not accused of wrongdoing. Challita did not respond to request for comment. The Herald has sighted eight prescriptions that four former colleagues say were obtained in their name but not at their request shortly after Challita asked for their Medicare details via text message which was also sighted by this masthead. Several colleagues, including a fifth staff member, also provided text messages from Challita purportedly asking them to give her Panadeine Forte from their own or their family's prescriptions. Paige Roy was employed as an educator at the centre and said that a few weeks into Challita starting as director, she asked her for her Medicare number to 'update employment records'. 'She said [the owner] was updating our portfolios on the company's childcare management system ... I just didn't think anything of it,' she said. Text messages between the pair allegedly show Challita asking for Roy's Medicare card on four separate occasions, with Challita using excuses including getting a new phone, updating Roy's emergency information and updating the staff management system.

Mini hearts to save cancer survivors from heart disease
Mini hearts to save cancer survivors from heart disease

The Advertiser

time12 hours ago

  • The Advertiser

Mini hearts to save cancer survivors from heart disease

Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts. Breast cancer survivors at risk of severe heart disease due to chemotherapy and other treatments could benefit from a new drug to protect them from cardiovascular illness. In Australia, more than 21,000 people are diagnosed with breast cancer and about 3300 die from the disease each year. But the treatments helping patients survive chemotherapy and antibody-based therapies are also putting them at risk of heart failure, arrhythmias or other cardiovascular conditions years later. Heart disease related to cancer treatment is emerging as a significant threat to breast cancer survivors, with 30 per cent going on to develop potentially life-threatening heart complications. A team of scientists at the Heart Research Institute are using lab-grown "mini hearts" - the size of a grain of sand created from patient blood samples - to test drugs that could one day be given alongside chemotherapy. "We currently have limited knowledge on why cardiotoxicity occurs and which women will be most impacted," lead researcher Professor Julie McMullen said. "This research has the opportunity to identify women at risk of cardiotoxicity before symptoms are present, so we can develop drugs to protect the heart during and after cancer treatment." A protective drug would have been vital for Lee Hunt, who has experienced long-term heart damage from rounds of chemotherapy and Herceptin, a targeted therapy medication. "You never recover after cancer, but I was doing well until about five years after my treatment finished and I started experiencing dizzy spells," Ms Hunt told AAP. "It turned out the chemotherapy had affected my heart and I have permanent heart weakness. It won't kill me but it does need to be managed carefully. "Cancer treatment may save your life but that needs to be a good quality of life." The heart damage could sometimes be worse than the cancer itself, HRI research officer Dr Clara Liu Chung Ming said. "We want to give patients a therapy that can be safely delivered with their cancer treatment, to protect the heart before any damage occurs," she said. "It's about saving hearts as well as lives." While the research project is still in the pre-clinical stage, its potential is significant. The microscopic 3D "mini heart" models mimic aspects of how the human heart functions. "Our mini hearts replicate how a real heart contracts and responds to stress," Dr Liu Chung Ming said. "We expose them to chemotherapy and see how they react, then introduce our drug and see if it helps." The next step in the project will be to use breast cancer patient blood samples to generate personalised mini hearts.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store